CN113318069A - Anti-inflammatory topical cream for treating psoriasis and preparation method thereof - Google Patents
Anti-inflammatory topical cream for treating psoriasis and preparation method thereof Download PDFInfo
- Publication number
- CN113318069A CN113318069A CN202110540244.9A CN202110540244A CN113318069A CN 113318069 A CN113318069 A CN 113318069A CN 202110540244 A CN202110540244 A CN 202110540244A CN 113318069 A CN113318069 A CN 113318069A
- Authority
- CN
- China
- Prior art keywords
- parts
- cream
- inflammatory
- papermulberry
- leaf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 73
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 229940100611 topical cream Drugs 0.000 title claims description 12
- 241000933832 Broussonetia Species 0.000 claims abstract description 100
- 239000006071 cream Substances 0.000 claims abstract description 82
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 28
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 28
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 28
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 20
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims abstract description 20
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 20
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 20
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 20
- 229950004959 sorbitan oleate Drugs 0.000 claims abstract description 20
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 18
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000008117 stearic acid Substances 0.000 claims abstract description 18
- 239000000758 substrate Substances 0.000 claims abstract description 12
- 239000011159 matrix material Substances 0.000 claims abstract description 10
- 229960004274 stearic acid Drugs 0.000 claims abstract description 9
- 239000000839 emulsion Substances 0.000 claims abstract description 8
- 238000000746 purification Methods 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 19
- 238000005303 weighing Methods 0.000 claims description 18
- 229940057995 liquid paraffin Drugs 0.000 claims description 16
- 229950008882 polysorbate Drugs 0.000 claims description 16
- 229920000136 polysorbate Polymers 0.000 claims description 16
- 239000003871 white petrolatum Substances 0.000 claims description 16
- 239000012154 double-distilled water Substances 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 230000008591 skin barrier function Effects 0.000 abstract description 12
- 230000002757 inflammatory effect Effects 0.000 abstract description 8
- 102000004127 Cytokines Human genes 0.000 abstract description 7
- 108090000695 Cytokines Proteins 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 20
- 239000003814 drug Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 8
- 208000002474 Tinea Diseases 0.000 description 8
- 241000130764 Tinea Species 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 6
- 230000000857 drug effect Effects 0.000 description 6
- 239000003674 animal food additive Substances 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 244000144730 Amygdalus persica Species 0.000 description 4
- 235000006040 Prunus persica var persica Nutrition 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229960002751 imiquimod Drugs 0.000 description 3
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000013309 psoriasis mouse model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an anti-inflammatory external cream for treating psoriasis, which comprises the following components in part by weight: the paper mulberry leaf cream is formed by combining an emulsion body and a substrate, wherein the main effective component of the emulsion body is a paper mulberry leaf extract; the matrix comprises one or more of hyaluronic acid, stearic acid, sorbitan oleate and potassium sorbate, so as to assist the anti-inflammatory component of the papermulberry leaf extract to act on the skin. The preparation method of the anti-inflammatory external cream for treating psoriasis comprises the purification of the effective components of the papermulberry leaf cream and the preparation of the anti-inflammatory cream and the substrate cream. The papermulberry leaf anti-inflammatory cream can reduce inflammatory cytokines in vivo by improving the skin barrier function, thereby playing an anti-inflammatory role.
Description
Technical Field
The invention relates to the field of traditional Chinese medicine preparations, in particular to an anti-inflammatory cream for treating psoriasis, and especially relates to an anti-inflammatory external cream for treating psoriasis and a preparation method thereof.
Background
Psoriasis is a common skin disease characterized by hyperproliferation of epidermis and chronic inflammatory reaction of dermis, and is mainly clinically manifested by erythema covered with silvery scales, also called psoriasis or pinking skin, lesions are erythema and pimple, are mostly distributed on the extending sides of limbs and scalp, and are itchy. Psoriasis is a chronic inflammatory disease, which cannot be completely cured and is usually recurrent.
In the process of implementing the technical solutions in the prior art, the applicant finds that the following technical problems exist in the technical solutions in the prior art:
in the prior art, as the main emerging treatment means for treating psoriasis at home and abroad is treatment by adopting biological agents, the treatment means has quick effect but high price, the maintenance time is different according to people, and long-term injection can generate drug resistance. The traditional treatment method is unsatisfactory in treatment effect, the recurrence is frequent, and other parts of treatment medicines are accompanied by liver affected injuries of different degrees.
Disclosure of Invention
On one hand, the technical problem to be solved by the invention is to provide the anti-inflammatory cream for treating psoriasis, solve the technical problems of high drug cost, non-ideal drug effect and great side effect in the prior art, and at least achieve one of the technical effects of reducing the drug cost, remarkably improving the drug effect and reducing the side effect.
In order to solve the technical problems, the technical scheme of the invention is as follows:
an anti-inflammatory topical cream for the treatment of psoriasis: the paper mulberry leaf cream is formed by combining an emulsion body and a substrate, wherein the main effective component of the emulsion body is a paper mulberry leaf extract; the matrix comprises one or more of hyaluronic acid, stearic acid, sorbitan oleate and potassium sorbate, so as to assist the anti-inflammatory component of the papermulberry leaf extract to act on the skin.
Preferably, the compound is prepared from the following raw materials:
dried papermulberry leaf, hyaluronic acid, white vaseline, light liquid paraffin, stearic acid, polysorbate, sorbitan oleate, potassium sorbate and water.
Preferably, the feed additive is prepared from the following raw materials in parts by weight:
80-120 parts of dry papermulberry leaf, 120 parts of hyaluronic acid, 100 parts of white vaseline, 140 parts of light liquid paraffin, 140 parts of stearic acid, 80-100 parts of polysorbate, 30-40 parts of sorbitan oleate, 1-5 parts of potassium sorbate and 2500 parts of water 1500.
Preferably, the feed additive is prepared from the following raw materials in parts by weight:
80-100 parts of dry papermulberry leaf, 114 parts of hyaluronic acid, 120 parts of white vaseline, 160 parts of light liquid paraffin 140, 120 parts of stearic acid, 80-88 parts of polysorbate, 30-32 parts of sorbitan oleate, 1-3 parts of potassium sorbate and 2000 parts of water 1500.
More preferably, the feed additive is prepared from the following raw materials in parts by weight:
120 parts of dry papermulberry leaf, 120 parts of hyaluronic acid 114, 140 parts of white vaseline, 180 parts of light liquid paraffin 140, 140 parts of stearic acid 120, 88-100 parts of polysorbate, 32-40 parts of sorbitan oleate, 3-5 parts of potassium sorbate and 2500 parts of water 2000.
Particularly preferably, the composition is prepared from the following raw materials in parts by weight:
100 parts of dry papermulberry leaf, 114 parts of hyaluronic acid, 120 parts of white vaseline, 140 parts of light liquid paraffin, 120 parts of stearic acid, 88 parts of polysorbate, 32 parts of sorbitan oleate, 3 parts of potassium sorbate and 2000 parts of water.
In another aspect, the invention provides a method for preparing an anti-inflammatory topical cream for treating psoriasis, comprising the steps of: comprises the purification of the effective components of the papermulberry leaf cream and the preparation of the anti-inflammatory cream and the substrate cream.
Preferably, the purification of the effective components of the papermulberry leaf cream comprises the following steps:
(A1) extracting main raw materials: weighing dry papermulberry leaf, adding into double distilled water, boiling in water bath, collecting liquid, adding into double distilled water again, repeating the above operation, and collecting extractive solution;
(A2) preparing a cleaning paste: adding the two collected extracting solutions into a rotary evaporator, recovering under reduced pressure, and finally collecting and weighing the concentrated pure paste.
More preferably, the anti-inflammatory cream and base cream formulation comprises the steps of:
(S1) hyaluronic acid dissolution: weighing hyaluronic acid, adding double distilled water, and sealing for overnight storage after hyaluronic acid is dissolved in water;
(S2) main component mixing: weighing white vaseline, light liquid paraffin, stearic acid, polysorbate and sorbitan oleate as oil phase components on the next day, mixing, and heating to 80-90 deg.C to obtain mixture A;
(S3) filtering the papermulberry leaf paste: weighing the papermulberry leaf paste, dissolving in double distilled water, filtering with a funnel with a filter paper sheet, and retaining the filtered liquid;
(S4) adding water and filtering: weighing double distilled water, adding filtered papermulberry leaf extract liquid, potassium sorbate and hyaluronic acid as water phase components, and heating to 80-90 deg.C to obtain mixture B;
(S5) stirring the mixture: mixing the mixture A and the mixture B, and stirring the mixture by using an electronic stirrer until all components are uniformly stirred to obtain a mixed solution C;
(S6) cream preparation: aging the mixed solution C in water bath at 45-55 deg.C for 65-75 hr to obtain cream A;
(S7) preparation of cream for external use: and (3) storing the cream A in a refrigerating chamber at the temperature of 3-5 ℃ for 15-20 hours, and subpackaging to obtain the papermulberry leaf anti-inflammatory external cream.
By adopting the technical scheme, the papermulberry leaf water-soluble extract is used as the main effective component, and the papermulberry leaf is sweet and cool and has no toxicity, and has the functions of dispelling wind and eliminating dampness, clearing heat and killing parasites, moistening skin and relieving itching, and treating itching body, tinea and malignant sore. The compendium records that the traditional Chinese medicine has the effects of promoting urination, removing rheumatism and swelling, whitish and turbid urine, hernia and tinea and sore. In the book, Ben Cao Hui Yan, cool blood, dispel wind and induce diuresis. Recorded in Shenghui Fang, the medicine is used for treating tinea and itching, and the papermulberry leaf is half jin, finely cut and pounded to be extremely rotten, and then applied to tinea. The papermulberry leaf can reduce inflammatory cytokines in vivo by improving the skin barrier function. So that the papermulberry leaf anti-inflammatory external cream can play the anti-inflammatory efficacy and exert the price advantage of the papermulberry leaf. The technical problems of high drug cost and unsatisfactory drug effect in the prior art are solved, and the technical effects of reducing the drug cost and remarkably improving the drug effect are achieved.
In addition, the papermulberry leaf is the leaf of the papermulberry, is a natural product in the nature, has good safety, does not have strong irritation to the human body, improves the medication safety of the papermulberry leaf anti-inflammatory external cream, and effectively reduces the side effect of medication.
Drawings
FIG. 1 is a graph showing the effect of papermulberry leaf extract on treating psoriasis;
FIG. 2 is an index graph of severity of psoriasis improved by the papermulberry leaf extract;
FIG. 3 is an index graph of the extract of papermulberry leaf effective in improving skin barrier function;
FIG. 4 is a graph showing the anti-inflammatory effect of TNF of the papermulberry leaf extract;
FIG. 5 is a graph showing the anti-inflammatory effects of IL6 and PCNA in the papermulberry leaf extract;
FIG. 6 is a graph showing the anti-inflammatory effects of papermulberry leaf extract IL17 and IL 23;
FIG. 7 is a first anti-inflammatory effect chart of the anti-inflammatory cream of papermulberry leaf and the control substrate cream applied to the left and right arms of the psoriasis subject respectively;
FIG. 8 is a second anti-inflammatory effect chart of the anti-inflammatory cream of papermulberry leaf and the control substrate cream applied to the left and right arms of the psoriasis subject respectively;
figure 9 is a graph of PASI scores of anti-inflammatory cream of papermulberry leaf on psoriasis subjects.
Detailed Description
The following further describes embodiments of the present invention with reference to the drawings. It should be noted that the description of the embodiments is provided to help understanding of the present invention, but the present invention is not limited thereto. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
Psoriasis is a common skin disorder characterized by excessive epidermal proliferation and chronic inflammatory response of the dermis. The prevalence rate of psoriasis in natural people is 0.1-3.0%. The existing clinical psoriasis treatment medicines have good short-term curative effect, but have large toxic and side effects, cannot be used for a long time, are easy to relapse and aggravate after stopping taking the medicines, have poor long-term curative effect and generate toxicity to important organs.
According to the technical scheme of the embodiment of the application, the anti-inflammatory external cream for treating psoriasis and the preparation method thereof are provided, so that the problems of high drug cost, non-ideal drug effect and great side effect in the prior art are solved, and the beneficial effects of reducing the drug cost, remarkably improving the drug effect and reducing the side effect are realized by adopting the papermulberry leaf water-soluble extract as the main active ingredient.
The general idea of the embodiment of the invention for solving the technical problems is as follows:
an anti-inflammatory topical cream for the treatment of psoriasis: the paper mulberry leaf cream is formed by combining an emulsion body and a substrate, wherein the main effective component of the emulsion body is a paper mulberry leaf extract; the matrix comprises one or more of hyaluronic acid, stearic acid, sorbitan oleate and potassium sorbate, so as to assist the anti-inflammatory component of the papermulberry leaf extract to act on the skin.
Specifically, the feed additive is prepared from the following raw materials:
dried papermulberry leaf, hyaluronic acid, white vaseline, light liquid paraffin, stearic acid, polysorbate, sorbitan oleate, potassium sorbate and water.
More specifically, the feed additive is prepared from the following raw materials in parts by weight:
80-120 parts of dry papermulberry leaf, 120 parts of hyaluronic acid, 100 parts of white vaseline, 140 parts of light liquid paraffin, 140 parts of stearic acid, 80-100 parts of polysorbate, 30-40 parts of sorbitan oleate, 1-5 parts of potassium sorbate and 2500 parts of water 1500.
In order to better understand the technical solution, the technical solution will be described in detail with reference to the drawings and the specific embodiments.
Example 1
The formulation of the anti-inflammatory topical cream for the treatment of psoriasis is as follows:
50g of dry papermulberry leaf, 52g of hyaluronic acid, 60g of white vaseline, 80g of light liquid paraffin, 60g of stearic acid, 44g of polysorbate, 16g of sorbitan oleate, 1.5g of potassium sorbate and 1000g of water
The preparation method of the anti-inflammatory external cream for treating psoriasis comprises the following steps:
one part is the extraction and purification of the effective components of the papermulberry leaf cream, and the other part is the preparation of the cream.
The separation, extraction and purification process of the anti-inflammatory effective components of the papermulberry leaf comprises the following steps:
step 1: weighing 50g of dry papermulberry leaf, adding into 1L of double distilled water, boiling in water bath for 30 minutes, collecting liquid, adding into 1L of double distilled water again, repeating the above operation, and collecting liquid;
step 2: adding the two collected extracting solutions into a rotary evaporator, recovering under reduced pressure, and finally collecting and weighing the concentrated pure paste.
The preparation of the papermulberry leaf anti-inflammatory cream and the substrate cream comprises the following steps:
step 1: weighing 2g of hyaluronic acid, adding 50ml of double distilled water, and sealing for overnight storage after the hyaluronic acid is dissolved in the water;
step 2: weighing 60g of white vaseline, 80g of light liquid paraffin, 60g of stearic acid, 44g of polysorbate and 16g of sorbitan oleate as oil phase components on the next day, mixing, and heating to 85 ℃ to obtain a mixture A;
and step 3: weighing 8g of the papermulberry leaf paste, dissolving the papermulberry leaf paste in 50ml of double distilled water, filtering the solution through a funnel with a filter paper sheet, and keeping the filtered liquid;
and 4, step 4: weighing 516.5g of double distilled water, adding filtered papermulberry leaf extract liquid, 1.5g of potassium sorbate and 50g of hyaluronic acid as water phase components, and heating to 85 ℃ to obtain a mixture B;
and 5: mixing the mixture A and the mixture B, and stirring for 30 minutes by using an electronic stirrer until all components are uniformly stirred to obtain a mixed solution C;
step 6: aging the mixed solution C in a water bath at 50 ℃ for 72 hours to prepare cream A;
and 7: and (3) storing the cream A in a refrigerating chamber at the temperature of 4 ℃ for 18 hours, and subpackaging to prepare the papermulberry leaf anti-inflammatory external cream.
Example 2
The dry papermulberry leaf in the example 1 is replaced by the fresh papermulberry leaf. The preparation is as described in example 1.
Comparative example
According to the procedure of example 1, a base cream was formulated without adding the papermulberry leaf extract as a control reference for efficacy evaluation.
Test of Effect of examples and comparative examples
The test data for the examples and the control examples mainly include anti-inflammatory efficacy, psoriasis treatment effect, improvement of skin barrier and the like, and animal experiments and human experiments are respectively performed.
The animal test of the anti-inflammatory cream of papermulberry leaf is described as follows:
step 1: C57B/6J mice were purchased and shaved on the back. The imiquimod is applied for 1 time every day, and after 3 days, the psoriasis-like skin lesions appear in the mice, so that the construction of a psoriasis mouse model is completed.
Step 2: the mice continued to remain on their backs on the imiquimod cream. Meanwhile, the anti-inflammatory cream of the papermulberry leaf is applied for 2 times every day, and the contrast group is the substrate cream prepared by applying every day, wherein the applying amount is 2mg +/-0.1 mg/cm 2. The rub lasted 7 days.
And step 3: within the dry expectations, the mouse home PASI score (psoriasis severity assessment index) was recorded daily.
And 4, step 4: and after the intervention period is finished, photographing to record the psoriasis state change of the mice, and detecting the skin barrier function index of the mice. Mouse serum and epidermis are collected, and the expression of inflammatory cytokines related to psoriasis is detected by ELISA and QPCR methods. Meanwhile, the skin tissues of the mice are collected to be pathological sections and immunohistochemistry.
The research result shows that different components of the papermulberry leaf extract can effectively improve the severity of psoriasis, and the figure 1 shows. In particular, psoriasis severity PASI scores decreased, skin lesions were reduced in thickness, and spleen weight was relatively normal, as shown in figure 2.
The papermulberry leaf extract effectively improves the skin barrier function of an imiquimod-induced psoriasis model mouse:
the papermulberry leaf extract is found to be effective in improving the skin barrier function of psoriasis model mice. The concrete indexes include water content, transdermal water loss speed and epidermal pH value, and the result is shown in figure 3.
The papermulberry leaf extract effectively reduces the expression of inflammatory factors related to psoriasis:
meanwhile, after the papermulberry fruit leaf extract is used for treating, the expression level of inflammatory cytokines related to psoriasis in the blood of each intervention group of mice is detected, and the papermulberry fruit leaf extract is found to be capable of effectively reducing the expression of inflammatory cytokines related to psoriasis, and the figure is shown in fig. 4-6.
The human test of the papermulberry leaf anti-inflammatory cream is described as follows:
in order to evaluate the anti-inflammatory efficacy of the anti-inflammatory cream of papermulberry leaf, relevant multicenter clinical cohort studies were performed after the experimental protocol was approved by the ethical committee.
Step 1: preparing anti-inflammatory cream and matrix cream of papermulberry leaf according to the preparation scheme
Step 2: the participants were selected according to the criteria for enrollment, and 20 psoriasis subjects were enrolled at the southern medical university dermatology hospital, the university dermatology hospital, and the plinth dermatology hospital, respectively, according to the design of the multicenter cohort study.
Step 2: the bent sides of the two forearms are used as the tested parts, and the tested parts should be kept dry to avoid contacting other external preparations before and during the test. Recording data such as bilateral arm PASI scores before intervention, a subject quality of life questionnaire DLQI, skin barrier function indexes, basic information and the like.
And step 3: uniformly applying the anti-inflammatory cream of papermulberry leaf to the skin lesion and normal part of the right arm of the subject 2 times a day according to the dosage of 2mg +/-0.1 mg/cm2, uniformly applying the cream matrix to the left arm of the subject 2 times a day according to the dosage of 2mg +/-0.1 mg/cm2, and continuously applying for 7 days.
And 4, step 4: after the intervention period is finished, detecting the water loss speed TEWL and the water content of the horny layer of the skin damage and non-skin damage positions of the arms at two sides and the barrier function recovery speed index through a Korean GPSKIN skin barrier function detector; PASI scores were recorded and photographed.
And 5: the test results show that the basic skin barrier function indexes of the anti-inflammatory paper mulberry leaf cream group and the matrix cream contrast group are statistically different, and the barrier repairing effect of the anti-inflammatory paper mulberry leaf cream is better than that of the contrast matrix cream. The papermulberry fruit leaf cream group has lower arm PASI score, and proves that the papermulberry fruit leaf anti-inflammatory cream can effectively improve the course of psoriasis and play a role of anti-inflammation.
The research result shows that the anti-inflammatory cream of the papermulberry peach leaves can effectively improve the psoriasis progress after the anti-inflammatory cream of the papermulberry peach leaves and the contrast substrate cream are respectively smeared on the left and right arms of the psoriasis subject for 2 weeks, and the chart is shown in fig. 7 and 8. Compared with the anti-inflammatory effect of the papermulberry leaf anti-inflammatory cream and the matrix, the papermulberry leaf anti-inflammatory cream can more effectively improve the moisture content of the epidermis of a psoriasis subject, improve the function of the epidermis and more effectively reduce the psoriasis PASI score compared with the cream matrix, as shown in figure 9.
And (3) analyzing test results:
firstly, the main effective components of the anti-inflammatory cream of the papermulberry peach leaves come from the papermulberry peach leaves which are sweet and cool and nontoxic, have the functions of dispelling wind and eliminating dampness, clearing heat and killing parasites, moistening skin and relieving itching, and treat tinea and malignant sore caused by wind. The compendium records that the traditional Chinese medicine has the effects of promoting urination, removing rheumatism and swelling, whitish and turbid urine, hernia and tinea and sore. In the book, Ben Cao Hui Yan, cool blood, dispel wind and induce diuresis. Recorded in Shenghui Fang, the medicine is used for treating tinea and itching, and the papermulberry leaf is half jin, finely cut and pounded to be extremely rotten, and then applied to tinea. In recent times, Mr. Zhao Zhan nan, a Chinese medicine dermatology department, is used as a medicated bath raw material for treating psoriasis. The safety and the efficacy are ensured to a certain extent; on the other hand, the papermulberry leaf does not enter the pharmacopoeia, and the application field is still less at present.
Secondly, the main function of the embodiment of the invention relates to the field of treatment of inflammatory skin diseases. The destruction of the skin barrier function causes the occurrence and aggravation of various inflammatory diseases, such as inflammatory skin diseases (psoriasis, eczema), type II diabetes, senile dementia, cardiovascular diseases, and the like. The anti-inflammatory cream of the papermulberry leaf can reduce inflammatory cytokines in vivo by improving the barrier function of skin, thereby playing an anti-inflammatory effect.
According to the analysis of experimental data, the papermulberry leaf anti-inflammatory cream can effectively treat psoriasis and exert anti-inflammatory effect. On one hand, in the experimental results of animal experiments, the anti-inflammatory cream with the papermulberry leaf as the main component can more effectively reduce the expression of inflammatory cytokines of psoriasis mice, reduce the psoriasis PASI score and effectively play the anti-inflammatory role; on the other hand, in human body experiments, the papermulberry leaf anti-inflammatory cream can effectively reduce the PASI score of the arms of patients, improve the skin barrier function and treat psoriasis. After the optimization is continued, the method has better effect and market prospect.
Example 2 similar effects were achieved with fresh papermulberry leaf.
The embodiments of the present invention have been described in detail with reference to the accompanying drawings, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, and the scope of protection is still within the scope of the invention.
Claims (9)
1. An anti-inflammatory topical cream for the treatment of psoriasis, characterized in that: the paper mulberry leaf cream is formed by combining an emulsion body and a substrate, wherein the main effective component of the emulsion body is a paper mulberry leaf extract; the matrix comprises one or more of hyaluronic acid, stearic acid, sorbitan oleate and potassium sorbate, so as to assist the anti-inflammatory component of the papermulberry leaf extract to act on the skin.
2. An anti-inflammatory topical cream for the treatment of psoriasis according to claim 1, characterised in that: the preparation method comprises the following steps of:
dried papermulberry leaf, hyaluronic acid, white vaseline, light liquid paraffin, stearic acid, polysorbate, sorbitan oleate, potassium sorbate and water.
3. An anti-inflammatory topical cream for the treatment of psoriasis according to claim 1, characterised in that: the feed is prepared from the following raw materials in parts by weight:
80-120 parts of dry papermulberry leaf, 120 parts of hyaluronic acid, 100 parts of white vaseline, 140 parts of light liquid paraffin, 140 parts of stearic acid, 80-100 parts of polysorbate, 30-40 parts of sorbitan oleate, 1-5 parts of potassium sorbate and 2500 parts of water 1500.
4. An anti-inflammatory topical cream for the treatment of psoriasis according to claim 3, characterised in that: the feed is prepared from the following raw materials in parts by weight:
80-100 parts of dry papermulberry leaf, 114 parts of hyaluronic acid, 120 parts of white vaseline, 160 parts of light liquid paraffin 140, 120 parts of stearic acid, 80-88 parts of polysorbate, 30-32 parts of sorbitan oleate, 1-3 parts of potassium sorbate and 2000 parts of water 1500.
5. An anti-inflammatory topical cream for the treatment of psoriasis according to claim 3, characterised in that: the feed is prepared from the following raw materials in parts by weight:
120 parts of dry papermulberry leaf, 120 parts of hyaluronic acid 114, 140 parts of white vaseline, 180 parts of light liquid paraffin 140, 140 parts of stearic acid 120, 88-100 parts of polysorbate, 32-40 parts of sorbitan oleate, 3-5 parts of potassium sorbate and 2500 parts of water 2000.
6. An anti-inflammatory topical cream for the treatment of psoriasis according to claim 3, characterised in that: the feed is prepared from the following raw materials in parts by weight:
100 parts of dry papermulberry leaf, 114 parts of hyaluronic acid, 120 parts of white vaseline, 140 parts of light liquid paraffin, 120 parts of stearic acid, 88 parts of polysorbate, 32 parts of sorbitan oleate, 3 parts of potassium sorbate and 2000 parts of water.
7. A process for the preparation of an anti-inflammatory cream for external use according to any one of claims 1 to 6 for the treatment of psoriasis, characterized in that: comprises the purification of the effective components of the papermulberry leaf cream and the preparation of the anti-inflammatory cream and the substrate cream.
8. A process for the preparation of an anti-inflammatory cream for external use for the treatment of psoriasis according to claim 7, characterised in that: the purification of the effective components of the papermulberry leaf cream comprises the following steps:
(A1) extracting main raw materials: weighing dry papermulberry leaf, adding into double distilled water, boiling in water bath, collecting liquid, adding into double distilled water again, repeating the above operation, and collecting extractive solution;
(A2) preparing a cleaning paste: adding the two collected extracting solutions into a rotary evaporator, recovering under reduced pressure, and finally collecting and weighing the concentrated pure paste.
9. A process for the preparation of an anti-inflammatory cream for external use for the treatment of psoriasis according to claim 7, characterised in that: the preparation of the anti-inflammatory cream and the base cream comprises the following steps:
(S1) hyaluronic acid dissolution: weighing hyaluronic acid, adding double distilled water, and sealing for overnight storage after hyaluronic acid is dissolved in water;
(S2) main component mixing: weighing white vaseline, light liquid paraffin, stearic acid, polysorbate and sorbitan oleate as oil phase components on the next day, mixing, and heating to 80-90 deg.C to obtain mixture A;
(S3) filtering the papermulberry leaf paste: weighing the papermulberry leaf paste, dissolving in double distilled water, filtering with a funnel with a filter paper sheet, and retaining the filtered liquid;
(S4) adding water and filtering: weighing double distilled water, adding filtered papermulberry leaf extract liquid, potassium sorbate and hyaluronic acid as water phase components, and heating to 80-90 deg.C to obtain mixture B;
(S5) stirring the mixture: mixing the mixture A and the mixture B, and stirring the mixture by using an electronic stirrer until all components are uniformly stirred to obtain a mixed solution C;
(S6) cream preparation: aging the mixed solution C in water bath at 45-55 deg.C for 65-75 hr to obtain cream A;
(S7) preparation of cream for external use: and (3) storing the cream A in a refrigerating chamber at the temperature of 3-5 ℃ for 15-20 hours, and subpackaging to obtain the papermulberry leaf anti-inflammatory external cream.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110540244.9A CN113318069A (en) | 2021-05-18 | 2021-05-18 | Anti-inflammatory topical cream for treating psoriasis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110540244.9A CN113318069A (en) | 2021-05-18 | 2021-05-18 | Anti-inflammatory topical cream for treating psoriasis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113318069A true CN113318069A (en) | 2021-08-31 |
Family
ID=77415860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110540244.9A Pending CN113318069A (en) | 2021-05-18 | 2021-05-18 | Anti-inflammatory topical cream for treating psoriasis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113318069A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115645458A (en) * | 2022-10-10 | 2023-01-31 | 黄河科技学院 | Application of broussonetia papyrifera leaf extract in preparation of psoriasis treatment medicine |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1867322A1 (en) * | 2006-06-12 | 2007-12-19 | M. Cristina Fernández Rodríguez | Topical composition for the treatment of psoriasis |
| CN105963633A (en) * | 2016-05-10 | 2016-09-28 | 四川省人民医院 | Composition containing volatile oil of curcuma rhizomes for treating psoriasis and preparation method of emulsifiable paste preparation thereof |
| CN106266876A (en) * | 2016-09-27 | 2017-01-04 | 泰山医学院 | A kind of for compound ointment treating eczema and preparation method thereof |
| CN107095906A (en) * | 2017-03-24 | 2017-08-29 | 蔡瑞康 | It is a kind of to treat psoriasis and Chinese medical extract and bathing instant granular with skin moistening and itch stopping effect |
| CN109745361A (en) * | 2018-11-08 | 2019-05-14 | 戴博 | It is a kind of to alleviate senile skin itch and the compound skin cream and its preparation method and application with moisturizing effect |
-
2021
- 2021-05-18 CN CN202110540244.9A patent/CN113318069A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1867322A1 (en) * | 2006-06-12 | 2007-12-19 | M. Cristina Fernández Rodríguez | Topical composition for the treatment of psoriasis |
| CN105963633A (en) * | 2016-05-10 | 2016-09-28 | 四川省人民医院 | Composition containing volatile oil of curcuma rhizomes for treating psoriasis and preparation method of emulsifiable paste preparation thereof |
| CN106266876A (en) * | 2016-09-27 | 2017-01-04 | 泰山医学院 | A kind of for compound ointment treating eczema and preparation method thereof |
| CN107095906A (en) * | 2017-03-24 | 2017-08-29 | 蔡瑞康 | It is a kind of to treat psoriasis and Chinese medical extract and bathing instant granular with skin moistening and itch stopping effect |
| CN109745361A (en) * | 2018-11-08 | 2019-05-14 | 戴博 | It is a kind of to alleviate senile skin itch and the compound skin cream and its preparation method and application with moisturizing effect |
Non-Patent Citations (4)
| Title |
|---|
| 刘素兰，王萍: "《药剂学 第3版》", 30 November 2020, 西安：西安交通大学出版社, pages: 189 - 195 * |
| 杨明，李小芳: "《药剂学 第2版》", 30 August 2018, 北京：中国医药科技出版社, pages: 165 - 168 * |
| 程秋生: "《皮肤病性病中医洗渍疗法》", 31 March 2004, 北京：科学技术文献出版社, pages: 65 - 66 * |
| 马振友等: "《皮肤美容化妆品制剂手册 第2版》", 31 January 2015, 北京：中医古籍出版社, pages: 85 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115645458A (en) * | 2022-10-10 | 2023-01-31 | 黄河科技学院 | Application of broussonetia papyrifera leaf extract in preparation of psoriasis treatment medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1947739B (en) | Traditional Chinese medicine composition for treating dermal titillation and chronic eczema and its preparation method | |
| CN101327286B (en) | Pain-relieving anti-inflammation medicament and preparation method thereof and use | |
| CN102772590A (en) | Traditional Chinese medicine composition, gel paste and preparation method | |
| CN113318069A (en) | Anti-inflammatory topical cream for treating psoriasis and preparation method thereof | |
| CN114569515A (en) | Hydrogel for repairing damaged skin barrier after medical and art and preparation method thereof | |
| CN112516250B (en) | Traditional Chinese medicine composition for treating psoriasis vulgaris and preparation method thereof | |
| Baker | Erythropoietic protoporphyria provoked by iron therapy | |
| CN102846762B (en) | Medicinal composition, use and preparation thereof | |
| CN102423342B (en) | Medicinal composition for preventing and treating skin eczema and skin pruritus, formulation and application | |
| CN102048682B (en) | Loratadine cream and application thereof | |
| CN112521389A (en) | Medicament and method for promoting wound healing | |
| CN110721274A (en) | External antipruritic and preparation method thereof | |
| CN106822093B (en) | Application of composition in preparation of medicine for treating angiogenesis abnormality | |
| WO2022242769A1 (en) | Use of pyridone derivative containing heteroatom cyclobutane substituent | |
| CN110302228A (en) | A kind of biological agent that treating hemorrhoid and its application | |
| TWI627952B (en) | Use of composition for preparing drug for modulating angiogenesis | |
| UA71605C2 (en) | Composition for treatment of psoriasis based on ethanol extract from human placenta | |
| CN115671234B (en) | Pharmaceutical composition for treating gout and preparation method and application thereof | |
| CN113384599B (en) | Porcupine animal medicine and preparation method and application thereof | |
| CN116869837B (en) | Anti-stinging and antiallergic composition and preparation method and application thereof | |
| CN108635530B (en) | External medicine for treating psoriasis | |
| CN107582694B (en) | One kind is dispelled tinea external preparation and preparation method thereof | |
| CN115969922B (en) | External traditional Chinese medicine composition for atopic dermatitis and eczema, dehumidification paste based on external traditional Chinese medicine composition and preparation method of dehumidification paste | |
| CN114272290B (en) | A topical compound Chinese medicinal extract for treating cancer pain of all steps, and its preparation method | |
| CN102274328A (en) | Medicament for treating psoriasis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 510000 Lujing Road, Guangzhou, Guangdong Applicant after: DERMATOLOGY HOSPITAL OF SOUTHERN MEDICAL University (GUANGDONG PROVINCIAL DERMATOLOGY HOSPITAL GUANGDONG SKIN DISEASE PREVENTION CENTER CHINA LEPROSY CONTROL RESEARCH CENTER) Address before: 510091 skin physiology and topical preparation R & D and evaluation center, 10th floor, Dermatology Hospital, Southern Medical University, No. 2 Lujing Road, Yuexiu District, Guangzhou, Guangdong Province Applicant before: DERMATOLOGY HOSPITAL OF SOUTHERN MEDICAL University |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |